Theodoros Karantanos
Theodoros Karantanos
1Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
3General Internal Medicine Section, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA
1,2,3,
Anthos Christofides
Anthos Christofides
1Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
1,2,
Kankana Bardhan
Kankana Bardhan
1Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
1,2,
Lequn Li
Lequn Li
1Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
1,2,
Vassiliki A Boussiotis
Vassiliki A Boussiotis
1Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
4Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA, USA
1,2,4,*
1Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
3General Internal Medicine Section, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA
4Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, MA, USA
Edited and Reviewed by: Barbara Fazekas De St Groth, University of Sydney, Australia
✉*Correspondence: Vassiliki A. Boussiotis, vboussio@bidmc.harvard.edu
Specialty section: This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology
Received 2016 Aug 10; Accepted 2016 Aug 26; Collection date 2016.
Keywords: T cells, T cell differentiation, T cell activation, tumor immunity, EZH2
Copyright © 2016 Karantanos, Christofides, Bardhan, Li and Boussiotis.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
